Skip to main content
. 2023 Dec 22;15(2):328–336. doi: 10.1021/acschemneuro.3c00646

Figure 1.

Figure 1

[3H]-l-deprenyl competition binding assays with non-radiolabeled SMBT-1 in frontal/temporal cortex CN and AD brain homogenates. Competition binding studies were performed in an increasing concentration range (10–15–10–5 M) of non-radiolabeled SMBT-1 against a single concentration of [3H]-l-deprenyl (10 nM) in (A) frontal and (B) temporal cortex brain homogenates from three CN and three AD subjects. Results are presented as means ± SEM of nine experiments in triplicate. AD, Alzheimer’s disease; CN, cognitively normal control; IC50, half-maximal inhibitory concentration. Frontal cortex: r2 = 0.779 AD and r2 = 0.768 CN; temporal cortex: r2 = 0.887 AD and r2 = 0.857 CN.